Covid-19 Vaccinations

DT0001390 FB (1080) Indigenous - Social

Covid-19 Vaccination

Gympie Road Medical Centre is a COVID-19 Vaccine Provider centre. 

We understand that you might have some questions and concerns regarding your immunisation. Please book a standard appointment with one of our GPs to go through your questions and concerns.

Who is eligible for Second Booster:


The Australian Technical Advisory Group on Immunisation (ATAGI) has recommended a second booster COVID-19 vaccine dose among the most vulnerable sections of the population.
Fourth dose of a COVID-19 vaccine is now recommended four months after an initial booster dose for the following groups:

  • All over-65s

  • Those aged 16 and above with severe immunocompromise, as listed below (If you are not the patient of our practice, please provide a letter of support from my GP)

  • Aboriginal and Torres Strait Islander people aged 50 and older

People with the following immunocompromising conditions and therapies for which a 3rd primary dose is recommended


N.B. This list is not exhaustive. Clinicians may use their judgement for conditions or medications that are not listed, and which are associated with severe immunocompromise.


  • Active haematological malignancy

  • Non-haematological malignancy with current active treatment (e.g. chemotherapy, whole body irradiation)

  • Solid organ transplant with immunosuppressive therapy

  • Haematopoietic stem cell transplant (HSCT) recipients or chimeric antigen receptor T-cell
    (CAR-T) therapy within 2 years of transplantation.

  • Immunosuppressive therapies including:

    • High dose corticosteroid treatment equivalent to >20mg/day of prednisone for ≥14 days in a month, or pulse corticosteroid therapy.

    • Multiple immunosuppressants where the cumulative effect is considered to be severely immunosuppressive.

    • Selected conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDS):

      • including mycophenolate, methotrexate (≥10 mg/week), leflunomide, azathioprine (≥ 1mg/kg day), 6-mercaptopurine (≥ 0.5mg/kg/day), alkylating agents
        (e.g. cyclophosphamide, chlorambucil), and systemic calcineurin inhibitors
        (e.g. cyclosporin, tacrolimus).

      • excluding hydroxychloroquine or sulfasalazine when used as monotherapy.

    • Biologic and targeted therapies anticipated to reduce the immune response to COVID-19 vaccine.

  • Primary immunodeficiency including combined immunodeficiency and syndromes, major antibody deficiency (e.g. common variable immune deficiency (CVID) or agammaglobulinemia), defects of innate immunity (including phagocytic cells), defects of immune regulation, complement deficiencies and phenocopies of primary immunodeficiencies.

  • Advanced or untreated HIV with CD4 counts <250/μL or those with a higher CD4 count unable to be established on effective anti-retroviral therapy.

    • a 3rd primary dose is not required for people living with HIV, receiving ART with CD4 counts ≥250/μL.

  • Long term haemodialysis or peritoneal dialysis.

Vaccine for children 5 to 11 years:

  • The Comirnaty (Pfizer) vaccine has been approved for children 5 to 11 years. The vaccine schedule for children is 2 doses, given 8 weeks apart. This interval can be shortened in special circumstances to a minimum of 3 weeks.

Here is some useful links for your review:

Information for parents and guardians

Information on COVID-19 Pfizer  vaccine

Preparing for COVID-19 vaccination

After your COVID-19 vaccination

After care sheet for Pfizer Vaccination

Consent form print here

Flu Vaccinations


Influenza Vaccination bookings

Vaccination against influenza this year is even more important. Covid and influenza are different viruses and Immunisation against one doesn’t provide the coverage for the other. With borders reopening a possible resurgence of influenza can occur in 2022. 

The highest level of protection occurs in the first 3 to 4 months following vaccination. Annual vaccination should ideally occur before the onset of each influenza season. This is usually from June to September in most parts of Australia but may be atypical this year. Vaccinating from April provides protection before the peak season.

Eligibility for influenza vaccines under the medicare:

  • children from 6 months to less than 5 years of age

  • adults aged 65 years and over

  • Aboriginal and Torres Strait Islander people aged 6 months and over

  • pregnant women (during any stage of pregnancy)

  • people aged 6 months and over with medical conditions which increase the risk of complications.

All other groups are not eligible to receive Influnaza vaccine under NIP. The influenza vaccine can be purchased form Chemsave Lawnton Pharmacy and would be administered by our nurses at the same time.

For more information about national influenza immunisation please click here